ClinicalTrials.gg
CompletedNCT00123591Updated Jan 12, 2017

Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury

A Phase 2 interventional study of activated recombinant human factor VII in Acquired Bleeding Disorder and Trauma, sponsored by Novo Nordisk A/S. Completed at 15 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial is conducted in Asia, Europe, Middle East, and North America. The primary objective of the trial is to evaluate the safety of Recombinant Activated Factor VII in patients with brain contusions. The secondary objective of the trial is to evaluate the preliminary efficacy of Recombinant Activated Factor VII in preventing early haemorrhagic progression in contusive brain injury.

02

Conditions studied

  • Acquired Bleeding Disorder
  • Trauma

Browse trials for

03

In context

Wounds and Injuries

2,217 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.

This study's enrollment of 96 is above the median of 70 across 1,424 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Contusive brain injury (including brain stem) diagnosed by history, clinical examination and confirmed by CT scan within 6 hours of onset
  • In British Columbia and Nova Scotia, subjects must be = 19 years.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (actual)
06

What researchers measure

Primary outcomes

  1. Evaluate the Safety of Recombinant Activated Factor VII in Subjects with Brain Contusions

    Time frame: Within the first 15 days of injury

Secondary outcomes

  1. Evaluate the preliminary efficacy of Recombinant Activated Factor VII in preventing haemorrhagic progression in brain contusions

07

Study locations

15 sites
  • Novo Nordisk Investigational Site
    Montreal, H3G 1A4, Canada
  • Novo Nordisk Investigational Site
    Helsinki, 00250, Finland
  • Novo Nordisk Investigational Site
    Hannover, 30625, Germany
  • Novo Nordisk Investigational Site
    New Dehli, New Delhi 110029, India
  • Novo Nordisk Investigational Site
    Bangalore, 560017, India
  • Novo Nordisk Investigational Site
    Haifa, 31096, Israel
  • Novo Nordisk Investigational Site
    Ramat Gan, 52621, Israel
  • Novo Nordisk Investigational Site
    Tel-Aviv, 64239, Israel
  • Novo Nordisk Investigational Site
    Cesena, 47023, Italy
  • Novo Nordisk Investigational Site
    Rotterdam, 3015 GD, Netherlands
  • Novo Nordisk Investigational Site
    Singapore, 119074, Singapore
  • Novo Nordisk Investigational Site
    Singapore, 308443, Singapore
  • Novo Nordisk Investigational Site
    Barcelona, 08035, Spain
  • Novo Nordisk Investigational Site
    Zürich, 8091, Switzerland
  • Novo Nordisk Investigational Site
    Taoyuan, 333, Taiwan
08

References and documents

Publications

  • Narayan RK, Maas AI, Marshall LF, Servadei F, Skolnick BE, Tillinger MN; rFVIIa Traumatic ICH Study Group. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery. 2008 Apr;62(4):776-86; discussion 786-8. doi: 10.1227/01.neu.0000316898.78371.74. PubMed 18496183 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Jul 25, 2005
Start
Jan 2005
Primary completionActual
May 2006
CompletionActual
May 2006
Last update
Jan 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00123591
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 25, 2005
Start date
Jan 2005
Primary completion
May 2006
Completion
May 2006
Last update
Jan 12, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion